Read by QxMD icon Read


Georgios-Marios Makris, Nikiforita Poulakaki, Aristea-Maria Papanota, Evgenia Kotsifa, Theodoros N Sergentanis, Theodora Psaltopoulou
BACKGROUND: Hidradenitis suppurativa (HS) is a chronic inflammatory disease that frequently involves the perineal and perianal regions. The association between HS and malignant transformation is a rare but under recognized phenomenon. OBJECTIVE: This systematic review aims to summarize all available cases of vulvar and perianal/perineal cancer emerging in patients with HS, describing clinical and therapeutic particularities of these coexisting conditions in female patients...
October 13, 2016: Dermatologic Surgery: Official Publication for American Society for Dermatologic Surgery [et Al.]
C Dessinioti, C Zisimou, V Tzanetakou, A Stratigos, C Antoniou
BACKGROUND: Limited data exist on the use of systemic antibiotic treatment for hidradenitis supportive (HS). AIM: To investigate the effectiveness, safety and relapse rate of HS treated with a combination of daily oral clindamycin and rifampicin. METHODS: This was a prospective, hospital-based study of oral clindamycin 600 mg and rifampicin 600 mg daily for 12 weeks for treatment of HS. Patients were followed up for 1 year to monitor for relapse...
October 18, 2016: Clinical and Experimental Dermatology
Dennis Wong, Scott Walsh, Raed Alhusayen
No abstract text is available yet for this article.
November 2016: Journal of the American Academy of Dermatology
Alexander H Fischer, Alessandra Haskin, Ginette A Okoye
BACKGROUND: Antibiotic therapy is commonly used to treat hidradenitis suppurativa (HS). Although concern for antibiotic resistance exists, data examining the association between antibiotics and antimicrobial resistance in HS lesions are limited. OBJECTIVE: We sought to determine the frequency of antimicrobial resistance in HS lesions from patients on antibiotic therapy. METHODOLOGY: A cross-sectional analysis was conducted on 239 patients with HS seen at the Johns Hopkins Medical Institutions from 2010 through 2015...
October 11, 2016: Journal of the American Academy of Dermatology
Alice Gottlieb, Alan Menter, April Armstrong, Christopher Ocampo, Yihua Gu, Henrique D Teixeira
BACKGROUND: Hidradenitis Suppurativa (HS), also known as acne inversa, is a painful, chronic, debilitating, inflammatory skin disease and has shown response to anti-TNF-α therapy. Efficacy and safety of the anti-TNF-α agent, adalimumab, was assessed in a post hoc analysis of women from the first 16 weeks of a phase 2 study of men and women with HS. METHODS: Patients with moderate-to-severe HS in at least 2 body areas, unresponsive or intolerant to oral antibiotics for treatment of their HS, and with no previous anti-TNF-a or systemic non-biologic treatment, were randomized 1:1:1 to 40 mg adalimumab-weekly or every-other-week, or placebo...
October 1, 2016: Journal of Drugs in Dermatology: JDD
R Andersen, G B E Jemec
Hidradenitis suppurativa (HS) is difficult to treat. Official guidelines have only recently been developed, and suggest that patients should be provided with both adjuvant, medical and surgical therapy. The guidelines are the result of resurgent interest in this disease, in which etiology and pathogenesis are only partially understood at present. Recent research has, however, identified possible targets for specific intervention using biologicals. In addition, classical clinically driven developments of new treatments continue to evolve, leading to several interesting new therapies for HS patients...
August 2016: Drugs of Today
George Denny, Milan J Anadkat
BACKGROUND: Treatment for hidradenitis suppurativa is often empiric and inadequate, and determining which patients will respond is difficult. OBJECTIVE: We sought to determine which patient factors are associated with a positive response to first-line medical therapy. METHODS: A single-center retrospective cohort study of all patients with hidradenitis suppurativa seen between January 1, 1992, and October 1, 2014, was conducted. Response to first-line medical therapy (oral/topical antibiotics, intralesional corticosteroids, and topical washes) was examined at follow-up within 6 months of initiating therapy...
September 28, 2016: Journal of the American Academy of Dermatology
Peter Theut Riis, Jurr Boer, Errol P Prens, Ditte M L Saunte, Inge E Deckers, Lennart Emtestam, Karin Sartorius, Gregor B E Jemec
BACKGROUND: Hidradenitis suppurativa (HS) is a chronic inflammatory disease of the hair follicle. Standard practice of managing acute flares with corticosteroid injection lacks scientific evidence. OBJECTIVE: We sought to assess the outcomes of routine treatment using intralesional triamcinolone (triamcinolone acetonide 10 mg/mL) in the management of acute flares in HS. METHODS: This was a prospective case series evaluating the effect of intralesional corticosteroids for alleviation of acute flares in HS...
September 28, 2016: Journal of the American Academy of Dermatology
João Vasco Santos, Carmen Lisboa, Caterina Lanna, Altamiro Costa-Pereira, Alberto Freitas
BACKGROUND/AIMS: Hidradenitis suppurativa (HS), a chronic inflammatory skin disease of the hair follicle, can lead to scarring and disability. With an estimated European prevalence of 1%, few epidemiological studies of HS have been performed, and none focused on hospitalisations. We aimed to study the time trends of HS hospitalisations and to evaluate the demographic characteristics, hospital incidence rate, readmissions, length of stay, comorbidities and risk factors of hospitalised HS patients...
September 30, 2016: Dermatology: International Journal for Clinical and Investigative Dermatology
Natanel Jourabchi, Alexander H Fischer, Ashley Cimino-Mathews, Kevin M Waters, Ginette A Okoye
Squamous cell carcinoma (SCC) arising from chronic hidradenitis suppurativa (HS) is rare; however, the morbidity associated with this presentation is high and management has not been standardised or optimised. We present a case of HS of the perineum and buttocks complicated by SCC, requiring multiple extensive surgical resections. Adjuvant radiotherapy was withheld initially because of concern for poor healing of the surgical wound but was eventually initiated after a second recurrence was identified. The patient ultimately expired 4 years after the initial diagnosis of SCC...
September 29, 2016: International Wound Journal
Esther S Kim, Karly P Garnock-Jones, Susan J Keam
Subcutaneous adalimumab (Humira(®)) is a tumour necrosis factor-α blocker that is the only approved agent for the treatment of moderate to severe hidradenitis suppurativa (HS) in several countries worldwide. This article reviews the clinical efficacy and safety of subcutaneous adalimumab in patients with moderate to severe HS. In clinical trials (PIONEER I and II), a greater proportion of adalimumab than placebo recipients reached HS clinical response (HiSCR) at week 12. The main secondary endpoints, such as the proportion of patients with an abscess and inflammatory nodule count of ≤2 at week 12, were significantly greater with adalimumab than with placebo in PIONEER II, but not in PIONEER I...
October 2016: American Journal of Clinical Dermatology
Sylke Schneider-Burrus, Ellen Witte-Haendel, Demetrios Christou, Benedetta Rigoni, Robert Sabat, Gerd Diederichs
BACKGROUND: Hidradenitis suppurativa (HS) is a chronic inflammatory disease, causing fistulating sinuses in the intertriginous skin of axillary, genitofemoral and perianal sites. OBJECTIVE: As other chronic inflammatory diseases, e.g. psoriasis, are frequently associated with spondyloarthropathies (SpA), the goal of this study was to quantify the prevalence of back pain and SpA in HS patients. METHODS: A prospective questionnaire survey in 100 HS patients and a retrospective evaluation of pelvic magnetic resonance imaging (MRI) scans in 46 HS patients were conducted...
September 21, 2016: Dermatology: International Journal for Clinical and Investigative Dermatology
María Jesús Suárez Valladares, Manuel Ángel Rodríguez Prieto, Ricard Serra Llusà
Photodynamic therapy is a common treatment in dermatology for several diseases, its main limitation is the penetration of photosensitizer and light in the tissue. However intralesional photodynamic therapy is a new technique where the photosensitizer and sometimes a 630nm laser beam are applied inside the lesión, so it allows achieve deeper penetration. It has been used to treat basal cell carcinoma, hidradenitis suppurativa or keloids.
September 16, 2016: Photodiagnosis and Photodynamic Therapy
Philippe A R R Pijls, Lennard P L Gilissen
BACKGROUND: The treatment of patients with inflammatory bowel diseases has been revolutionized by the introduction of biological therapy with TNF-alpha blockers. However, TNF-alpha blockers are also associated with a wide variety of dermatological side effects, such as local skin infections, psoriasis and eczema. A new biological therapy, targeting the gut-specific adhesion molecule alpha4beta7 integrin, is the humanized monoclonal IgG1 antibody vedolizumab. Vedolizumab prevents leukocyte migration to the gastrointestinal tract, thereby reducing inflammation...
September 1, 2016: Digestive and Liver Disease
WenChieh Chen, Gerd Plewig
Hidradenitis suppurativa/acne inversa is a diverse, enigmatic and distressful disease that has aroused growing interest in specialists from different disciplines. Both names describe its classical manifestations in the intertriginous regions and reflect the historical view of the disease definition, but cause confusions in the understanding of its pathogenesis and classification. In light of the advance in clinical, histopathological and pathophysiological findings, we propose the term "dissecting terminal hair folliculitis" (DTHF) to characterize its disease nature as folliculitis instead of acneiform disease or apocrine gland disorder...
September 13, 2016: Experimental Dermatology
Don Hoang, Vivi Chen, Sepideh Saber, Ketan Patel, Joseph Carey
The authors present a new technique in surgically treating hidradenitis suppurativa (HS), a debilitating skin condition. In HS, surgical treatment is often the best option because of the high recurrence rates despite extensive medical treatment. A commonly successful surgical method is using skin flaps after excision of the affected area. A superficial inferior epigastric artery flap is demonstrated here as a new alternative approach to treating a case of extensive HS of the groin. By using the pedicled superficial inferior epigastric artery flap for groin reconstruction, inguinal HS can be widely excised and reconstructed with minimal donor-site morbidity and a good aesthetic outcome...
August 2016: Plastic and Reconstructive Surgery. Global Open
Noah Scheinfeld
Combinations of rifampin and clindamycin or rifampin, metronidazole, and moxifloxcin have been reported as effective treatments for hidradenitis suppurativa (HS) Hurley Stage 1 and Hurley Stage 2.  Clinical trials suggest that for stage 1 and mild stage 2 HS, clindamycin 300 mg twice daily and rifampin 300 mg twice daily for 10 weeks can substantially abate HS in ~80% of cases and remit HS in ~50% of cases.  Another study notes use of rifampin-moxifloxacin-metronidazole given for 6 weeks, dosed as rifampin (10 mg/kg once daily), moxifloxacin (400 mg daily), and metronidazole (500 mg thrice daily) with the metronidazole stopped at week 6...
2016: Dermatology Online Journal
Allard R J V Vossen, Hessel H van der Zee, Armanda J Onderdijk, Jurr Boer, Errol P Prens
A body type with a high waist circumference or elevated waist-to-hip ratio (WHR), known as the "apple" body type, represents central/visceral obesity and is associated with the metabolic syndrome. The aim of this study was to simultaneously investigate the body mass index (BMI) and WHR in order to classify body types in individuals with hidradenitis suppurativa (HS) compared with a general dermatological population. A hospital-based cross-sectional study was performed in the Netherlands. One hundred and six HS patients and 212 controls were included...
September 8, 2016: Journal of Dermatology
Falk G Bechara, Schapoor Hessam
No abstract text is available yet for this article.
September 2016: MMW Fortschritte der Medizin
(no author information available yet)
Hidradenitis suppurativa is a recurring chronic inflammatory debilitating skin disease of the hair follicle that usually presents with painful, deep-seated and inflamed lesions in the apocrine gland-bearing areas of the body. The lesions often progress to become chronic with purulent discharge, sinus formation and scarring. Hidradenitis suppurativa is associated with systemic comorbidities, including metabolic syndrome and inflammatory bowel disease.(1) Long-term treatment is often necessary and requires coordination between primary care, dermatologists and surgeons...
September 2016: Drug and Therapeutics Bulletin
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"